DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20181496

The study of risk factors and prognostic indicators in patients with bacteremia due to ESBL producing organisms

Vasudeva Acharya, Varun Reddy G., Biji Bob Thomas

Abstract


Background: There is a growing incidence of extended-spectrum beta-lactamases (ESBL) infections worldwide. ESBL bacteremias have been associated with poor outcomes, higher costs and increased durations of hospital stay. The objective of the study was to identify the risk factors in these patients along with antibiotic susceptibility patterns to help identify the patients with poorer prognosis and in guiding treatment decisions more effectively.

Methods: An observational case-control study conducted in a tertiary care hospital in south India over a duration of 18 months. Cases were defined as an adult in-patient who had infection with blood cultures showing growth of ESBL-producing bacteria. A total of 70 patients were included in the study group and subjected to evaluation to determine the risk factors, prognostic indicators and the antibiotic susceptibility.

Results: The major risk factors for ESBL-bacteremia identified were prior admission, prior antibiotic usage, prior Foleys catheter and the presence of a vascular catheter. Pneumonia as the source of bacteremia and requirement of mechanical ventilation were identified as indicators of poor prognosis. Carbapenems, cefoperazone-sulbactam and piperacillin-tazobactam showed excellent sensitivity against ESBL-bacteremia.

Conclusions: The findings of this study emphasizes the importance of recognizing ESBL-bacteremias in patients with risk factors, so that patients who are at risk to have a worse prognosis can be promptly started on a susceptible antibiotic.


Keywords


Bacteremia, Catheter related infections, ESBL, Mechanical ventilation, Pneumonia

Full Text:

PDF

References


Kliebe C, Nies BA, Meyer JF, Tohdorff-Neutzling RM, Wiedemann B. Evolution of plasmid-coded resistance to broad-spectrum Ceph3|OSp0i'il'iS. Antimicrob Agents Chemother. 1985;28(2):302-7.

Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type beta-lactamases. Antimicrob Agents Chemother. 2002;46(l):1-11.

Kang Cl, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections due to extended- spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother. 2004;48(12):4574-81.

Paterson DL, K0 WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta- lactamases. Clin Infect Dis. 2004;39(1):31-7.

Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase- producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32(8):1162-71.

Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann lntern Med. 1993;119(5):353-8.

Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2006;50(4):l257-62.

Sankar S, Narayanan H, Kuppanan S, Nandagopal B. Frequency of extended-spectrum beta- Iactamase (ESBL)-producing Gram-negative bacilli in a 200-bed muIti-specialty hospital in Vellore district, Tamil Nadu, India. Infection. 2012;40(4):425-9.

Perry JD, Naqvi SH, Mirza IA, Alizai SA, Hussain A, Ghirardi S, et al. Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. J Antimicrob Chemother. 2011 Oct;66(10):2288-94.

Jena J, Debata NK, Subudhi E. Prevalence of extended-spectrum-beta-lactamase and metallo-beta-lactamase producing multi drug resistance gram- negative bacteria from urinary isolates. lndianJ Med Microbiol. 2013;31(4):420-1.

Ahmed SM, Rajeevan S, Jasmin PT, Shakir VPA. Detection of ESBL among the Gram negative uropathogens and their antibiotic resistance pattern in a rural medical college hospital North Kerala, India. International Journal of Current Microbiology and Applied Sciences. 2014;3(2):561-7.

Medeiros AA. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis. l997 Jan;24(1):S19-45.

Rodriguez-Bano J, Picon E, Gijon P, Hernandez JR, Ruiz M, Pena C, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 2010 Jan 1;50(1):40-8.

Tumbarello M, Spanu T, Sanguinetti M, Citton R, Montuori E, Leone F, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother. 2006;50(2):498-504.

Wu Ul, Yang CS, Chen WC, Chen YC, Chang SC. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli. J Microbiol lmmunol Infect. 2010;43(4):310-6.

Kim BN, Woo JH, Kim MN, Ryu J, Kim VS. Clinical implications of extended-spectrum beta-lactamase producing Klebsiella pneumoniae bacteraemia. Hosp Infect. 2002;S2(2):99-106.

Menashe G, Borer A, Yagupsky P, Peled N, Gilad J, Fraser D, et al. Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis. 2001;33(3):188-93.

Park SH, Choi SM, Lee DG, Kim L, Choi JH, Kim SH, et al. Emergence of extended-spectrum beta-lactamase-producing escherichia coli as a cause of community-onset bacteremia in South Korea: risk factors and clinical outcomes. Microb Drug Resist. 2011;17(4):537-44.

Abhilash KP, Veeraraghavan B, Abraham OC. Epidemiology and outcome of bacteremia caused by extended spectrum beta-lactamase (ESBL)~producing Escherichia coll and Klebsiella spp. in a tertiary care teaching hospital in south lndia. J Assoc Physicians India. 2010;58 Suppl:13474.

Kang Cl, Kim SH, Kim DM, Park WB, Lee KD, Kim HB, et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended spectrum beta-lactamase producing Klebsiella pneumonia. Infect Control Hosp Epidemiol. 2004;25(10):860-7.

Quirante OF, Cerrato SG, Pardos SL. Risk factors for bloodstream infections caused by extended spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Braz Infect Dis. 20l1;15(4):370-6.

Mosqueda-Gomez JL, Montano-Loza A, Rolon AL, Cervantes C, Bobadilla-del-Valle JM, Silva‘Sanchez J, et al, . Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study. Lnt J infect Dis. 2008;12(6):653-9.

Kang Cl, Chung DR, Ko KS, Peck KR, Song JH. Korean Network for Study of infectious D. Risk factors for infection and treatment outcome of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol. 2012;91(1):115-21.

Lee CC, Lee NY, Yan JJ, Lee HC, Chen PL, Chang CM, et al. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacter cloacae: role of carbapenem therapy. Antimicrob Agents Chemother. 2010;54(9):3S51-6.

Skippen I, Shemko M, Turton J, Kaufmann ME, Palmer C, Shetty N. Epidemiology of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp.: a nested case-control study from a tertiary hospital in London. J Hosp Infect. 2006;64(2):115-23.

Freeman JT, McBride SJ, Nisbet MS, Gamble GD, Williamson DA, Taylor SL, et al. Bloodstream infection with extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiaw care hospital in New Zealand: risk factors and outcomes. lntl Infect Dis. 2012;16(5):e371-4.

Sahiy H, Schubert S, Harder J, Kleine M, Sandvang D, Ullmann U, et al. Activity of human beta-defensins 2 and 3 against ESBL-producing Klebsiella strains. J Antimicrob Chemother. 2006;57(3):562-5.

Ortega M, Marco F, Soriano A, Aimela M, Martinez JA, Munoz A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother. 2009;63(3):568-74.

Tuon FF, Kruger M, Terreri M, Penteado-Filho SR, Gortz L. Klebsiella ESBL bacteremia-mortality and risk factors. BrazJ Infect Dis. 2011;15(6):594-8.

Behar PR, Teixeira PJ, Fachel JM, Kalil AC. The effect of control group selection in the analysis of risk factors for extended spectrum beta-lactamase-producing Klebsiella pneumoniae infections. A prospective controlled study. J Hosp Infect. 2008;68(2):123-9.

Melzer IVI, Petersen I4 Mortality following bacteraemic infection caused by extended spectrum beta~lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 2007;55(3):24-9.

Marra AR, Wey SB, Castelo A, Gales AC, Cal RG, Filho JR, et al. Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. BMC Infect Dis. 2006 Feb 14;6:24.

VA AR, Shenoy S, Yadav T. The antibiotic susceptibility patterns of uropathogenic Escherichia coli, with special reference to the fluoroquinolones. Journal of clinical and diagnostic research: JCDR. 2013 Jun;7(6):1027.